Chang Mei-Hwei, Chen Ding-Shinn
Department of Pediatrics, National Taiwan University Hospital, Taipei 10016, Taiwan Hepatitis Research Center, National Taiwan University Hospital, Taipei 10016, Taiwan.
Hepatitis Research Center, National Taiwan University Hospital, Taipei 10016, Taiwan Internal Medicine, National Taiwan University Hospital, Taipei 10016, Taiwan Genomics Research Center, Academia Sinica, Nankang 11529, Taiwan.
Cold Spring Harb Perspect Med. 2015 Mar 2;5(3):a021493. doi: 10.1101/cshperspect.a021493.
Hepatitis B virus (HBV) causes life-threatening liver disease. It is transmitted through a horizontal route or a mother-to-infant route, and the latter is the major route in endemic areas. Prevention of HBV infection by immunization is the best way to eliminate HBV-related diseases. The HBV vaccine is the first human vaccine using a viral antigen from infected persons, which is safe and effective. Either passive immunization by hepatitis B immunoglobulin (HBIG) or active immunization by HBV vaccine is effective, and a combination of both yields the best efficacy in preventing HBV infection. The impact of universal HBV immunization is huge, with 90%-95% effectiveness in preventing chronic HBV infection. It is the first cancer preventive vaccine with a protective efficacy against hepatocellular carcinoma (HCC) of ∼ 70%. Nevertheless, further effort is still needed to avoid vaccine failure and to increase the global coverage rate.
乙型肝炎病毒(HBV)可引发危及生命的肝脏疾病。它通过水平传播途径或母婴传播途径传播,在流行地区,后者是主要传播途径。通过免疫接种预防HBV感染是消除HBV相关疾病的最佳方法。HBV疫苗是第一种使用来自感染者病毒抗原的人类疫苗,安全有效。通过乙型肝炎免疫球蛋白(HBIG)进行被动免疫或通过HBV疫苗进行主动免疫均有效,两者联合使用在预防HBV感染方面疗效最佳。普遍接种HBV疫苗的影响巨大,在预防慢性HBV感染方面有效率达90% - 95%。它是第一种对肝细胞癌(HCC)具有约70%保护效力的癌症预防疫苗。然而,仍需进一步努力以避免疫苗接种失败并提高全球覆盖率。